Galapagos Unveils Low-Toxicity CAR-T Data From ATALANTA-1 In Relapsed Non-Hodgkin's Lymphoma

Galapagos NV (GLPG) presented positive Phase 1/2 data for GLPG5101, a CAR-T cell therapy for relapsed/refractory non-Hodgkin's lymphoma, at the EHA Congress. The ATALANTA-1 study demonstrated a favorable safety profile, low patient attrition (5%), and rapid delivery of fresh CAR-T cells within 7 days using Galapagos' decentralized manufacturing platform. These results suggest improved access to CAR-T therapy by reducing manufacturing times and potentially expanding eligibility for patients who might otherwise be excluded.

Analysis

Galapagos NV (GLPG) has presented encouraging new clinical data from its ATALANTA-1 Phase 1/2 study for GLPG5101, a CD19 CAR-T cell therapy candidate for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). The results, shared at the 30th European Hematology Association Congress, highlight a favorable safety profile with low rates of high-grade toxicities; most Grade ≥3 adverse events were hematologic, and instances of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) were predominantly low-grade, with only one Grade 3 case of each. Critically, Galapagos's decentralized manufacturing platform demonstrated its feasibility, enabling rapid delivery of fresh, early-memory-enriched CAR-T cells to 95% of leukapheresed patients (61 out of 64), with 89% of these infusions occurring within 7 days without requiring cryopreservation or cytotoxic bridging therapy. This rapid turnaround contributed to a patient attrition rate of just 5%, markedly lower than typical industry standards. Durable CAR-T persistence was observed for up to 21 months, suggesting potential for long-term efficacy. Company officials emphasized that this decentralized approach could significantly improve patient access to CAR-T therapy by reducing manufacturing times and potentially expanding eligibility to patients who might otherwise be excluded. Despite this positive clinical update, GLPG's stock is currently trading at $28.66, reflecting a minor decrease of 0.73% on the Nasdaq, indicating the market may be digesting this early-stage data or reacting to broader factors.

Key Decisions for Investors

• Investors should view the positive Phase 1/2 data for GLPG5101, particularly the low toxicity, rapid manufacturing turnaround, and low patient attrition, as a significant de-risking event and a potential long-term value driver for Galapagos NV.
• Monitor closely the continued clinical development of GLPG5101, including progression to later-stage trials, and the expansion progress of Galapagos's decentralized manufacturing capabilities in Europe and the U.S., as these are key catalysts for future growth.
• Consider the potential for Galapagos's decentralized manufacturing model to disrupt the CAR-T therapy landscape by improving accessibility and reducing logistical hurdles, which could provide a competitive advantage if successfully scaled and validated further.